Product Pathways - Neuroscience
LRRK2 Antibody #5559
|5559S||100 µl (10 western blots)||---||In Stock||---|
|5559||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Mouse, Rat||Endogenous||290||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
LRRK2 Antibody detects endogenous levels of total LRRK2 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu1848 of human LRRK2 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Western blot analysis of extracts from mouse LRRK2-/- and wild-type tissue using LRRK2 Antibody (upper) and TrkB (80E3) Rabbit mAb #4603 (lower). (Mouse wild-type and LRRK2-/- brains were kindly provided by Dr. Jie Shen, Brigham and Women's Hospital and Harvard Medical School, Boston, MA).
Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmarks of PD are progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem (1). Research studies have shown various genes and loci are genetically linked to PD including α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2 (2).
Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. Research studies have linked at least 20 LRRK2 mutations to PD, with the G2019S mutation being the most prevalent (3). The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length that leads to progressive neurite loss and decreased neuronal survival (4). Researchers are currently testing the MLK inhibitor CEP-1347 in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD (5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7727 Biotinylated Protein Ladder Detection Pack
- 2506 CDK5 Antibody
- 2306 DARPP-32 (19A3) Rabbit mAb
- 5560 DJ-1 (D21E11) Rabbit mAb
- 4211 Parkin (Prk8) Mouse mAb
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 2516 REDD1 Antibody
- 6883 SignalFire™ ECL Reagent
- 12757 SignalFire™ Elite ECL Reagent
- 12630 SignalFire™ Plus ECL Reagent
- 2680 p35/25 (C64B10) Rabbit mAb
- 4179 α-Synuclein (D37A6) XP® Rabbit mAb
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.